MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly - Gorse, Geoffrey J.; Grimes, Stephen; Buck, Helen; Mulla, Hussain; White, Peter; Hill, Heather; May, Jeanine; Frey, Sharon E.; Blackburn, Peter (Vaccine, 2022)
Keywords: Adjuvant; Adjuvants; Adjuvants, Immunologic; Aged; Aged, 80 and over; Allergy and Immunology; Alzheimer's disease; Antibodies; Antibodies, Viral; Antibody Formation; Antigens; Blood; blood serum; Clinical trials; cross reaction; Cross-reactivity; Dosage; Durability; elderly; Guillain-Barre syndrome; Headache; Health care; hemagglutination; Hemagglutination inhibition; Hemagglutination inhibition antibody; Hemagglutination Inhibition Tests; Hemagglutinins; Humans; Hypotheses; Immunogenicity; Influenza; Influenza vaccine; Influenza Vaccines; Influenza, Human; Injection; injection site; Laboratories; Morbidity; mortality; Myalgia; Older people; Reactogenicity; Safety; Seasons; Seroconversion; Urinalysis; Vaccination; Vaccine efficacy; Vaccines; Water; Thailand; Phuket Thailand; CRP; FDA; CDC; T1D; GMFI; ALT; DT; Hemagglutination inhibition antibody; SD; WBC; Adjuvant; Influenza vaccine; AST; ISR; Physical examination; GMT; HAI; Immunogenicity; IIV; MAS-1; HA; HD; Reactogenicity; CPK; QIV; hemagglutination inhibition; C-reactive protein; hemagglutinin; alanine aminotransferase; geometric mean fold increase; injection site reaction; geometric mean titer; Centers for Disease Control and Prevention; quadrivalent inactivated influenza vaccine; Mercia adjuvant system-1; standard dose; Type 1 diabetes mellitus; Diphtheria toxoid; white blood cell; creatine phosphokinase; U.S. Food and Drug Administration; inactivated influenza virus vaccine; high dose; PE; aspartate amino transferase